⚠️ *Are you aware of the new safety warnings surrounding medroxyprogesterone acetate (MPA)?*
The South African Health Products Regulatory Authority (SAHPRA) has clarified crucial information regarding the potential **MPA meningioma risk** associated with prolonged use of this synthetic hormone. While the absolute risk remains low, the implications for patients and healthcare providers are significant.
Dive into the article to understand the updated guidelines and what they mean for clinical practice.
#SyenzaNews #healthcare #oncology #HealthEconomics